CepTor CORP Form 8-K September 12, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) September 11, 2006

CepTor Corporation

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-32496 (Commission File Number) 200 International Circle, Suite 5100 Hunt Valley, Maryland (Address of Principal Executive Offices)

(410) 527-9998

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

11-2897392 (IRS Employer Identification No.)

> 21030-1350 (Zip Code)

Item 8.01 Other Events.

On September 11, 2006, Ceptor Corporation (the "Company") issued a press release announcing that on August 29, 2006, the Company submitted a Complete Response to questions received from the United States Food and Drug Administration regarding the Company's Investigational New Drug Application for Myudor, a treatment for Duchenne muscular dystrophy.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CEPTOR CORPORATION

Date: September 12, 2006

By: <u>/s/ William H. Pursley</u> William H. Pursley Chairman and Chief Executive Officer